- Home
- VTMX vs DNLI Comparison
VTMX vs DNLI Comparison
Compare VTMX & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTMX
- DNLI
- Stock Information
- Founded
- VTMX 1998
- DNLI 2013
- Country
- VTMX Mexico
- DNLI United States
- Employees
- VTMX N/A
- DNLI N/A
- Industry
- VTMX
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTMX
- DNLI Health Care
- Exchange
- VTMX Nasdaq
- DNLI Nasdaq
- Market Cap
- VTMX 2.3B
- DNLI 2.1B
- IPO Year
- VTMX 2023
- DNLI 2017
- Fundamental
- Price
- VTMX $27.08
- DNLI $13.69
- Analyst Decision
- VTMX Sell
- DNLI Strong Buy
- Analyst Count
- VTMX 2
- DNLI 15
- Target Price
- VTMX $27.50
- DNLI $33.85
- AVG Volume (30 Days)
- VTMX 184.5K
- DNLI 1.6M
- Earning Date
- VTMX 07-24-2025
- DNLI 07-31-2025
- Dividend Yield
- VTMX 2.58%
- DNLI N/A
- EPS Growth
- VTMX N/A
- DNLI N/A
- EPS
- VTMX 0.13
- DNLI N/A
- Revenue
- VTMX $258,927,122.00
- DNLI N/A
- Revenue This Year
- VTMX $17.35
- DNLI N/A
- Revenue Next Year
- VTMX $11.82
- DNLI $335.74
- P/E Ratio
- VTMX $20.52
- DNLI N/A
- Revenue Growth
- VTMX 15.06
- DNLI N/A
- 52 Week Low
- VTMX $21.30
- DNLI $10.57
- 52 Week High
- VTMX $32.84
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- VTMX 37.76
- DNLI 45.12
- Support Level
- VTMX $27.03
- DNLI $13.68
- Resistance Level
- VTMX $27.82
- DNLI $14.88
- Average True Range (ATR)
- VTMX 0.47
- DNLI 0.74
- MACD
- VTMX -0.27
- DNLI -0.03
- Stochastic Oscillator
- VTMX 7.48
- DNLI 34.91
About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)
Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.